Lester J. Lambert

Lester J. Lambert

Auto-generated profile, based on publicly available information

Lester J. Lambert

Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NBNicole Bata
Nicole Bata
Apirat ChaikuadApirat Chaikuad
Apirat Chaikuad
NBNicole A. Bakas
Nicole A. Bakas
ALAllison S. Limpert
Allison S. Limpert
LLLester J. Lambert
Lester J. Lambert
NCNicholas D. P. Cosford
Nicholas D. P. Cosford

10 December 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DRDhanya Raveendra-Panickar
Dhanya Raveendra-Panickar
DFDarren Finlay
Darren Finlay
FLFabiana Izidro Layng
Fabiana Izidro Layng
LLLester J. Lambert
Lester J. Lambert
MCMaria Celeridad
Maria Celeridad
LTLutz Tautz
Lutz Tautz
Disturbance of the dynamic balance between tyrosine phosphorylation and dephosphorylation of signaling molecules, controlled by protein tyrosine kinases and protein tyrosine phosphatases (PTPs), is known to lead to the development of cancer. While most approved targeted cancer therapies are tyrosine kinase inhibitors, PTPs have long been stigmatized as undruggable and have only recently gained renewed attention in drug discovery. One PTP target is the Src-homology 2 domain–containing phosphatase 2 (SHP2). SHP2 is implicated in tumor initiation, progression, metastasis, and treatment resistance, primarily because of its role as a signaling nexus of the extracellular signal–regulated kinase pathway, acting upstream of the small GTPase Ras. Efforts to develop small molecules that target SHP2 are ongoing, and several SHP2 allosteric inhibitors are currently in clinical trials for the treatment of solid tumors. However, while the reported allosteric inhibitors are highly effective against cells expressing WT SHP2, none have significant activity against the most frequent oncogenic SHP2 variants that drive leukemogenesis in several juvenile and acute leukemias. Here, we report the discovery of novel furanylbenzamide molecules as inhibitors of both WT and oncogenic SHP2. Importantly, these inhibitors readily cross cell membranes, bind and inhibit SHP2 under physiological conditions, and effectively decrease the growth of cancer cells, including triple-negative breast cancer cells, acute myeloid leukemia cells expressing either WT or oncogenic SHP2, and patient-derived acute myeloid leukemia cells. These novel compounds are effective chemical probes of active SHP2 and may serve as starting points for therapeutics targeting WT or mutant SHP2 in cancer.

10 September 2025 in bioRxiv
Verified
Preprint
Open access
FLFabiana Izidro A. L. Layng
Fabiana Izidro A. L. Layng
HRHuiyu Ren
Huiyu Ren
NBNicole A. Bakas
Nicole A. Bakas
DPDhanya R. Panickar
Dhanya R. Panickar
LLLester J. Lambert
Lester J. Lambert
NCNicholas D. P. Cosford
Nicholas D. P. Cosford
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including non-small cell lung cancer (NSCLC). We previously reported SBP-7455 , a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2, and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501 , two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, both as a single agent as well as in combination with current therapies.

12 February 2026 in ACS Chemical Biology
Verified
Journal Article
Closed access
FLFabiana Izidro A. L. Layng
Fabiana Izidro A. L. Layng
HRHuiyu Ren
Huiyu Ren
NBNicole A. Bakas
Nicole A. Bakas
DPDhanya R. Panickar
Dhanya R. Panickar
LLLester J. Lambert
Lester J. Lambert
NCNicholas D. P. Cosford
Nicholas D. P. Cosford

15 October 2025 in bioRxiv
Verified
Preprint
Open access
PHPatrick M. Hagan
Patrick M. Hagan
HRHuiyu Ren
Huiyu Ren
SBSonja N. Brun
Sonja N. Brun
FLFabiana I. A. Layng
Fabiana I. A. Layng
DPDhanya R. Panickar
Dhanya R. Panickar
NCNicholas D. P. Cosford
Nicholas D. P. Cosford
KRAS mutations drive tumorigenesis in multiple cancer types, including lung and pancreatic cancer. Autophagy is a cell survival pathway that supports tumor growth under metabolic stress and has been proposed to be a potential therapeutic avenue specifically in KRAS mutant cancers. The Unc-51-like ATG-activating kinases 1 and 2 (ULK) initiate the earliest regulated steps of autophagy and are the only protein kinases in the canonical autophagy pathway, thus making them attractive therapeutic targets for KRAS mutant tumors. We show here that genetic depletion of ULK1 or ATG13, core components of the ULK1 complex, in KRAS mutant lung and pancreatic cancer cell lines results in growth inhibition. Previously, we developed small molecule ULK1 inhibitors that not only inhibit ULK kinase activity but also induced the degradation of other core members of the ULK complex including ATG101 and ATG13. Therefore, we developed a high-throughput screening (HTS) assay in which ATG13 was HiBiT-tagged in KRAS mutant lung cancer cells to evaluate ULK inhibitors for ATG13 degradation. Using this approach, we discovered a lead ULK inhibitor, SBP-1750 , that potently inhibited ULK activity, promoted robust ATG13 degradation, impaired ATG, and induced KRAS mutant cancer cell death. Studies in a KRAS-mutant orthotopic syngeneic pancreatic cancer model show that oral treatment with SBP-1750 significantly reduced tumor growth. Pharmacokinetic analysis of SBP-1750 indicates favorable drug exposure and pharmacodynamic analysis confirms ATG13 degradation in vivo, mirroring in vitro results. Finally, immunohistochemical staining of orthotopic pancreatic tumors reveals a significant increase in CD4⁺ and CD8⁺ T cell infiltration upon treatment, suggesting that SBP-1750 enhances anti-tumor immunity. These findings support further development of SBP-1750 as a novel ATG-targeting cancer therapy.

7 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JFJoseph Fromm
Joseph Fromm
AAAlexander Aleshin
Alexander Aleshin
LLLester J. Lambert
Lester J. Lambert
LBLaurent J. S. De Backer
Laurent J. S. De Backer
SGSanthi Reddy Ganji
Santhi Reddy Ganji
NCNicholas D. P. Cosford
Nicholas D. P. Cosford
Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target. ABSTRACT FIGURE: